Stugeron 15mg Tablets

  • Name:

    Stugeron 15mg Tablets

  • Company:
    info
  • Active Ingredients:

    Cinnarizine

  • Legal Category:

    Supply through pharmacy only

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 03/09/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 3/9/2018

Click on this link to Download PDF directly

Johnson & Johnson (Ireland) Ltd

Johnson & Johnson (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name ACTIFED 30 mg/1.25 mg per 5 ml Syrup Active Ingredients Pseudoephedrine Hydrochloride, triprolidine hydrochloride
Medicine Name ACTIFED 60 mg / 2.5 mg Tablets Active Ingredients Pseudoephedrine Hydrochloride, triprolidine hydrochloride
Medicine Name Arret 2mg Hard Capsules Active Ingredients Loperamide Hydrochloride
Medicine Name Benylin Children's Chesty Coughs Active Ingredients Guaifenesin
Medicine Name Benylin Children's Dry Coughs Active Ingredients Diphenhydramine Hydrochloride, Levomenthol
Medicine Name Benylin Cough Medicine Syrup Active Ingredients Diphenhydramine Hydrochloride, Levomenthol
Medicine Name Benylin Day and Night Tablets Active Ingredients Diphenhydramine Hydrochloride, Paracetamol, Pseudoephedrine Hydrochloride
Medicine Name Benylin Dry Coughs Syrup Active Ingredients Dextromethorphan Hydrobromide, Diphenhydramine Hydrochloride, Levomenthol
Medicine Name Benylin Dual Action Dry Syrup Active Ingredients Dextromethorphan Hydrobromide, Pseudoephedrine Hydrochloride, triprolidine hydrochloride
Medicine Name Benylin Four Flu Tablets Active Ingredients Diphenhydramine Hydrochloride, Paracetamol, Pseudoephedrine Hydrochloride
Medicine Name Benylin Non- Drowsy for Chesty Coughs Active Ingredients Guaifenesin, Levomenthol
Medicine Name BENYLIN Non-Drowsy Dry Coughs, Syrup Active Ingredients Dextromethorphan Hydrobromide
Medicine Name Benylin Phlegm Cough plus Decongestant Syrup Active Ingredients Guaifenesin, Pseudoephedrine Hydrochloride
Medicine Name Benylin Phlegm Cough Syrup Active Ingredients Guaifenesin, Levomenthol
Medicine Name Calpol 120mg/5ml Infant Oral Suspension Active Ingredients Paracetamol
Medicine Name Calpol Infant 120mg/5ml Sugar Free Oral Suspension (bottle) Active Ingredients Paracetamol
Medicine Name Calpol Infant 120mg/5ml Sugar Free Oral Suspension (sachets) Active Ingredients Paracetamol
Medicine Name CALPOL Six Plus 250mg/5ml Oral Suspension Active Ingredients Paracetamol
Medicine Name CALPOL SIX PLUS 250mg/5ml SUGAR/COLOUR FREE ORAL SUSPENSION Active Ingredients Paracetamol
Medicine Name CALPOL Six Plus Fastmelts 250 mg Paracetamol OrodispersibleTablets Active Ingredients Paracetamol
Medicine Name Daktarin 2% w/w Cream Active Ingredients Miconazole nitrate
Medicine Name Daktarin 2% w/w Cutaneous Powder Active Ingredients Miconazole nitrate
Medicine Name DAKTARIN 20mg/g Oral Gel Active Ingredients Miconazole
Medicine Name Imodium 2 mg Capsules Active Ingredients Loperamide Hydrochloride
Medicine Name Imodium Instants 2mg Orodispersible Tablets Active Ingredients Loperamide Hydrochloride
1 - 0 of 65 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 3 September 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 3 September 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Updated on 2 May 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

CCDS updates and QRD

Updated on 26 April 2018 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects

Updated on 14 December 2017 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.8 –  New text added as introductory paragraph as per below –

 

The safety of Stugeron was evaluated in 372 cinnarizine treated subjects who participated in 7 placebo-controlled, double-blind clinical trials for the indications peripheral circulatory disorders, cerebral circulatory disorders, vertigo and seasickness; and in 668 cinnarizine treated subjects who participated in 6 comparator and 13-open label clinical trials for the indications of peripheral circulatory disorders, cerebral circulatory disorders and vertigo. Based on pooled safety data from these clinical trials, the most commonly reported (>2% incidence) Adverse Drug Reactions (ADRs) were: Somnolence (8.3%) and Weight Increased (2.1%).

 

Deleted below texts –

 

The safety of STUGERON was evaluated in 167 cinnarizine-treated subjects who participated in 1 placebo controlled trial (166 placebo-treated subjects) in the prophylaxis of seasickness. In this trial, only Somnolence has been included as an ADR with an incidence of 8.4% in the cinnarizine group compared to 4.8% in the placebo group.

 

Updated with blue texts as per below as applicable

 

Including the above mentioned ADR, the following ADRs have been observed from clinical trials and post-marketing experiences reported with the use of STUGERON. Frequencies displayed use the following convention:

 

Tabulated presentation of section 4.8 updated as per below – Uncommon frequency column has been added.

Nausea, Hypersomnia, Lethargy, Hyperhidrosis, Stomach Discomfort, Vomiting; Abdominal Pain Upper; Dyspepsia, Fatigue, weight increased has been added.

Lichenoid Keratosis moved from Not known to Uncommon frequency.

Hypersensitivity, Headache, Dry mouth and Gastrointestinal disorder were deleted.

System Organ Class

Adverse Drug Reactions

Frequency Category

Common

(≥ 1/100 to < 1/10)

Uncommon

(≥1/1,000 to <1/100)

Not Known

 

Nervous System

Disorders

Somnolence

Hypersomnia; Lethargy

Dyskinesia;

Extrapyramidal Disorder;

Parkinsonism; Tremor

Gastrointestinal disorders

Nausea

Stomach Discomfort;

Vomiting; Abdominal Pain Upper; Dyspepsia

 

Skin and subcutaneous

tissue disorders

 

Hyperhidrosis; Lichenoid Keratosis

Lichen Planus;

Subacute Cutaneous Lupus Erythematosus

 

Musculoskeletal and Connective Tissue Disorders

 

 

Muscle rigidity

General Disorders and Administration Site Conditions

 

Fatigue

 

Investigations

Weight Increased

 

 

 

 

Section 10: date of revision of text is updated with 06 December 2017.

Updated on 14 December 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 11 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 11 December 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 5 - how to store or dispose
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 12 August 2015 PIL

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 7 August 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Addition of the following text to Section 4.8

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Updated on 21 January 2014 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.9 - Overdose

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.4:

FROM:

As with other antihistamines, Stugeron may cause epigastric upset, which may be diminished if taken after meals.

 

Cinnarizine is a vasodilator.  While it has not been found to reduce blood pressure significantly, it should be used with caution in those with coronary artery disease or in patients with hypotension.

 

In patients with Parkinson's disease, Stugeron should only be given if the advantages outweigh the possible risk of aggravating this disease.

 

Stugeron may cause somnolence, especially at the start of treatment.  Therefore, caution should be taken when alcohol or CNS depressants are used concomitantly.

 

Because of its antihistamine effect, Stugeron may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.

 

Use of cinnarizine should be avoided in porphyria.

 

There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency.

 

Patients with rare hereditary problems of galactose intolerance, fructose intolerance, LAPP lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

 

Avoid alcoholic drink.

 

Warning:  Do not exceed the stated dose.

TO:

As with other antihistamines, Stugeron may cause epigastric upset, which may be diminished if taken after meals.

 

Cinnarizine is a vasodilator.  While it has not been found to reduce blood pressure significantly, it should be used with caution in those with coronary artery disease or in patients with hypotension.

 

In patients with Parkinson's disease, Stugeron should only be given if the advantages outweigh the possible risk of aggravating this disease.

 

Stugeron may cause somnolence, especially at the start of treatment.  Therefore, caution should be taken when alcohol or CNS depressants or tricyclic antidepressants are used concomitantly. (See section 4.5).

 

Diagnostic Interference:

Because of its antihistamine effect, Stugeron may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing. (See section 4.5).

 

Use of cinnarizine should be avoided in porphyria.

 

There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency.

 

Patients with rare hereditary problems of galactose intolerance, fructose intolerance, LAPP lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

 

Avoid alcoholic drink.

 

Warning:  Do not exceed the stated dose.


Section 4.5:

added:

Diagnostic interference:

Because of its antihistamine effect, Stugeron may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.


Section 4.6:

'Fertility' added to title.

Section 4.9:

Deleted:

Within the first hour after ingestion, gastric lavage may be performed.

Updated on 26 November 2010 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.8:

Side effects listed in table along with frequency

Section 5.1:

ATC code added

Section 5.2

More detiled information added for Distribution, Metabolism and Elimination

Section 5.3
Information added where previously no information was available.

Updated on 24 November 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 25 March 2010 SmPC

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 6.3: Shelf life chnaged from 5 to 3 years

Updated on 30 September 2009 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 31 August 2009 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

None provided

Updated on 25 August 2009 PIL

Reasons for updating

  • New PIL for medicines.ie